PERI-EDU University Education
Vitamin D participates in mineral homeostasis, immune regulation and bone remodelling. This biological relevance does not justify routine testing of every implant candidate, a universal dental target or high-dose supplementation without a medical indication.
Vitamin D physiology in context
Vitamin D is a fat-soluble prohormone obtained through cutaneous synthesis, food and supplements. Vitamin D3 and D2 undergo hepatic 25-hydroxylation to form 25-hydroxyvitamin D, the principal circulating status marker. The kidney and several extra-renal tissues can convert it to active 1,25-dihydroxyvitamin D.
| Component | Principal role | Interpretive boundary |
|---|---|---|
| Vitamin D3 and D2 | Precursors from skin, diet or supplements. | Intake does not predict serum status precisely because sun exposure, absorption and body composition differ. |
| 25(OH)D | Main circulating marker used to assess vitamin D status. | Assay variability and different guideline thresholds affect classification. |
| 1,25(OH)2D | Active ligand regulating transcription through the vitamin D receptor. | Usually unsuitable for routine status assessment because PTH, calcium, phosphate and kidney function tightly regulate it. |
| Parathyroid hormone | Maintains calcium balance and influences renal activation of vitamin D. | Elevation may reflect vitamin D deficiency, CKD, calcium intake or another cause. |
25(OH)D is reported in ng/mL or nmol/L. One ng/mL equals 2.5 nmol/L. Milligrams per millilitre are not an appropriate clinical unit.
VDR signalling and osteoimmunology
Active vitamin D binds the vitamin D receptor, which forms a heterodimer with the retinoid X receptor. The complex interacts with vitamin D response elements and modifies gene transcription. The response depends on cell type, differentiation stage, local cytokines and mineral availability.
- Vitamin D influences osteoblast differentiation, extracellular matrix proteins and signals that regulate osteoclast formation.
- Controlled osteoclast activity remains necessary for remodelling of injured bone.
- Osteocytes connect mineral regulation and mechanical loading with skeletal adaptation.
- VDR signalling can modify macrophage, antimicrobial and T-cell responses.
- Mechanistic immune effects do not prove that supplementation prevents peri-implantitis.
Osseointegration requires an initial inflammatory phase, vascular ingrowth, woven bone formation and subsequent remodelling. Osteoblasts and osteoclasts should not be reduced to competing good and bad cells.
What implant research currently supports
Animal studies commonly report impaired bone-to-implant contact with deficiency and improved histological measures after replacement. Human evidence includes observational cohorts, small trials and case reports. It suggests a possible relationship with early healing, but remains too heterogeneous for a universal implant-specific threshold or supplementation protocol.
| Evidence type | Typical finding | Main limitation |
|---|---|---|
| Animal studies | Deficiency can impair new bone formation and supplementation may improve bone-to-implant contact. | Models and doses do not directly represent routine human care. |
| Observational studies | Lower 25(OH)D sometimes accompanies early failure or less favourable bone outcomes. | Smoking, periodontal history, diabetes, season and supplementation can confound results. |
| Small clinical trials | Some report improved radiographic bone measures after correction. | Sample sizes, outcomes and regimens differ. |
| Systematic reviews | Biological plausibility and a possible positive association are consistent themes. | Few high-quality randomized trials limit certainty. |
Correcting documented deficiency supports general skeletal health but cannot compensate for infection, poor surgical technique, unstable loading or inadequate plaque control.
Interpreting 25(OH)D
The Food and Nutrition Board uses the following general interpretation. These categories are not implant eligibility thresholds.
| 25(OH)D concentration | General interpretation | Implant dentistry boundary |
|---|---|---|
| <12 ng/mL (<30 nmol/L) | Associated with deficiency and risk of osteomalacia. | Requires medical evaluation but does not independently prove that an implant will fail. |
| 12 to <20 ng/mL | Generally considered inadequate for bone and overall health. | Interpret with symptoms, risk factors and the planned procedure. |
| ≥20 ng/mL | Generally adequate for most healthy people. | No validated implant-specific benefit threshold exists. |
| >50 ng/mL | Linked to potential adverse effects, especially at higher levels. | Do not pursue high concentrations as a dental optimization goal. |
Some laboratories and older guidelines use 30 ng/mL as a target in selected clinical care. The 2024 Endocrine Society guideline states that outcome-specific thresholds have not been established for generally healthy adults and recommends against routine screening in this population.
A value between 20 and 29 ng/mL should not automatically cancel implant surgery in an otherwise healthy patient. The complete medical, local and procedural risk profile matters.
Who may need targeted assessment
Testing becomes more reasonable when the result may change medical treatment, clarify a suspected metabolic disorder or inform a complex regenerative plan in a high-risk patient.
- Suspected osteomalacia, bone pain, muscle weakness or abnormal mineral results.
- Osteoporosis, fragility fracture or established metabolic bone disease.
- Chronic kidney disease and CKD-mineral and bone disorder.
- Malabsorption, inflammatory bowel disease or bariatric surgery.
- Liver disease or medicines affecting vitamin D metabolism.
- Repeated unexplained early implant failure after reassessment of local and biomechanical causes.
Extensive augmentation or a history of impaired healing may justify a broader review than a straightforward single implant in a healthy adult. This is risk-based assessment, not evidence for a universal laboratory panel.
Supplementation and safety
The implant procedure alone does not justify a fixed high-dose regimen. Dose selection depends on age, baseline status, diet, absorption, kidney function, comorbidity and concurrent medicines.
- Use established medical regimens for documented deficiency.
- Do not prescribe 10,000 IU/day as a universal dental correction dose.
- For adults aged 50 years or older with an indication for treatment, current Endocrine Society guidance favours daily lower doses over intermittent high doses.
- The adult tolerable upper intake level of 4,000 IU/day is a safety limit for chronic unsupervised intake, not a routine target.
- Review calcium and 25(OH)D when high-dose treatment, renal disease or another medical risk justifies monitoring.
Excess vitamin D can cause hypercalcaemia and hypercalciuria, potentially leading to nausea, weakness, polyuria, nephrolithiasis, renal injury, soft-tissue calcification and arrhythmia.
Cofactors without supplement stacking
| Nutrient | Relevant biology | Clinical boundary |
|---|---|---|
| Magnesium | Supports many enzymes and contributes to PTH secretion and vitamin D metabolism. | Supplement for dietary inadequacy, documented deficiency or another medical indication; use caution in renal impairment. |
| Vitamin K | Required for gamma-carboxylation of proteins including osteocalcin. | Evidence does not support routine K2 supplementation for implant success; vitamin K interacts with vitamin K antagonists. |
| Vitamin A | Retinoid receptors participate in RXR-dependent nuclear signalling. | High preformed vitamin A intake can be toxic and may harm bone. |
| Calcium | Provides mineral substrate for the skeleton. | Assess diet and medical need before supplementation. |
Adding K2, magnesium or vitamin A does not neutralize vitamin D toxicity or remove the need for dose limits. Record all over-the-counter preparations.
A proportionate clinical pathway
- Review risk: assess skeletal, kidney and gastrointestinal disease, diet, medications and prior healing.
- Define the procedure: describe implant number, augmentation and healing burden.
- Use targeted tests: when indicated, interpret 25(OH)D with calcium, phosphate, PTH, alkaline phosphatase or kidney function.
- Coordinate treatment: refer suspected deficiency, osteomalacia or CKD-MBD to the responsible clinician.
- Reassess timing: proceed, adapt or defer using the complete risk profile rather than one threshold.
- Maintain local control: treat periodontal disease, optimize hygiene and monitor healing.
Clinical synthesis
- Use serum 25(OH)D as the usual status marker.
- Do not use 30 ng/mL as a universal implant eligibility threshold.
- Avoid routine screening of every healthy implant candidate.
- Consider targeted testing in metabolic bone disease, malabsorption, CKD or repeated unexplained failure.
- Human evidence suggests an association but does not establish a universal protocol.
- Avoid automatic high-dose vitamin D and routine K2, magnesium or vitamin A combinations.
- Continue to prioritize infection control, surgical technique, stability, loading and maintenance.
Download the full educational material
The full PDF expands vitamin D metabolism, VDR signalling, osteoimmunology, current implant evidence, laboratory interpretation and supplementation safety.
Download the full educational material (PDF)
Selected references
- Demay MB, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024.
- NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. Updated 2025.
- Werny JG, et al. Does vitamin D have an effect on osseointegration of dental implants? Int J Implant Dent. 2022;8:16.
- Buzatu BLR, et al. Impact of Vitamin D on Osseointegration in Dental Implants. Nutrients. 2024;16:209.
- Kwiatek J, et al. Impact of 25-hydroxycholecalciferol and deficiency treatment on bone level during osseointegration. J Clin Med. 2021;10:526.
Explore related PERI-EDU resources
#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #VitaminD #Osteoimmunology #Osseointegration #ImplantHealing
This material supports risk-based assessment and interdisciplinary communication. It does not replace diagnosis or treatment of vitamin D deficiency, metabolic bone disease, kidney disease or malabsorption by the responsible clinician.
This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.